# Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

> **NCT06775236** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 410 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Breast Cancer

## Interventions

- **DRUG:** SYS6010 jnjection
- **DRUG:** monotherapy chemotherapy
- **DRUG:** SYH2051 tablets

## Key facts

- **NCT ID:** NCT06775236
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2027-06-15
- **Final completion:** 2028-01-15
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775236, "Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06775236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*